Histogentics Raises $49M to Regenerate Knee Cartilage
July 25, 2012
Share:
Regenerative medicine company Histogenics has closed on a $49 million round of Series A financing led by Sofinnova Ventures. The funding will go towards completing Phase 3 trials for NeoCart, a neocartilage tissue implant for patients with knee cartilage damage that uses the patient's own cells to regenerate cartilage.
